Tumori Journal Abstract Book - October 2020 - 125

E - Breast Cancer
therapy since the advent of CDK4/6i combined with endocrine therapy (ET).
Patients and Methods: ER+/HER2- MBC patients
referred to our Institution from January 2011 to December
2019 and treated with CDK4/6i in association with ET as
1-2 lines settings were included.
Results: 61 patients were included; median age was 61
years (range 35-78). As first line, 45.9% received CDK4/6i
+ ET, 31.1% ET and/or Everolimus and 23% chemotherapy. mPFS was respectively not reached vs 16 months(m)
vs 20.9m (p=0.0231). There was a relevant but not statistically significant difference of mPFS between patients
treated with or without neo/adjuvant chemotherapy
(35.83m vs 18.33m) (p=0.5362). Patients hormone-naïve
showed a longer mPFS (31.03m) compared to ones treated
with adjuvant ET (22.17m) (p=0.9108). Patients with visceral disease (VD) had poor mPFS (17.53m vs 31.03m)
(p=0.3088). 67.6% of patients in first line setting had VD
progression. 56.7% of patients received a second line: 54%
CDK4/6i + ET (mPFS: 5.53m), 22% ET +/- Everolimus
(mPFS: 5.1m) and 24% chemotherapy (mPFS: 4.25m)
(p=0.0948). VD was correlated to poor prognosis (7.47m
vs 4.33m) (p=0.4242). 83.9% of patients in second line
had VD progression. Patient treated with CDK4/6i + ET
in second line after ET showed a longer mPFS of 9.57m,
compared to after chemotherapy (4.47m). About CDK4/6i
+ ET in first line setting, 8.8% received ET +/- Everolimus
in second line, while 5.8% chemotherapy, reporting a
longer mPFS (3.015m vs 5.65m respectively) (p=0.1707).
Conclusions: Our study confirms the benefit in PFS using
CDK4/6i + ET as first line of treatment in patients with
ER+/HER2- advanced breast cancer, according to literature. Our results suggest that this therapeutic strategy is
recommended in second line if not used previously.
Finally, chemotherapy seems to be the better option after
CDK4/6i, although further prospective studies will be necessary to define the best therapeutic strategy.

E49
When cancer affects gender
identity: looking in the mirror
and feeling different. Experience
of Women With Breast Cancer
Ricci F.1, Rossi L.2, Fontana A.1, Angelini F.3, Tomao S.4, Gozzi E.2
1

Ospedale Santa Maria Goretti, Latina; 2Università La Sapienza di Roma,
Aprilia; 3Ospedale Regina Apostolorum Albano Laziale, Albano; 4Università La
Sapienza di Roma, Roma

Background: Breast cancer (BC) is the leading cause of
cancer death in women worldwide. Breast is a symbol of
femininity, motherhood and sexuality: it represents women's gender identity. Within the basic oncological procedures - surgery, chemotherapy, radiotherapy, and hormone
therapy- there will be a lot of changes in the body.

125
The trauma of being diagnosed and treated for breast cancer can impact greatly on women's gender identity and
bodily image. The aim of our study was to evaluate the
influence and changes of BC on the bodily image and the
impact on women's quality of life.
Patients and methods: We enrolled 54 BC pts, mean age
was 54 years.
Participants were invited to complete a structured questionnaire which included four close-up questions regarding selfimage, before and after BC and its treatments, and the
impact of changes to body image on women's quality of life.
Results: 3/54 pts (5.5%) refused to participate in our
study. Of 51 participants, 22 (43.13%) had worsened selfimage after BC. 15 pts (68.1%) feeling of losing control
over one's own body and 7 (31.8%) had low moods, anxiety and feelings of shame. 19 pts (86.3%) had negative
impact on their quality of life: they stayed at home and
neglected some of their duties. Worsened self-image
occurred after BC diagnosis in 15 pts (68.1%) while in 7
pts (31.8%) after BC treatment.
Conclusions: Our results suggest that changes of BC on
the bodily image can negative impact on women's quality
of life and functioning in society. In our experience most
patients have had a worsening of their body image before
BC treatment. Focusing on pts's bodily image before starting treatment could prepare pts for the treatment outcomes
and the changes that await them.

E50
HER 2 LOW BREAST CANCER: FROM
THE STATE OF THE ART TO FUTURE
DEVELOPMENTS
Cubeddu A.1, Fusco O.1, Pastorini A.1, Menatti E.1, Caponigro G.1,
Cantini S.1, Deligiannis P.1, Bertolini A.2, Maiolani M.2, Declich P.3,
Prada M.3, Poletti P.4, Grechi A.4, Franzini P.4, Fregoni V.5
1
ASST della Valtellina e Alto Lario-Oncologia Medica, Sondrio; 2ASST della
Valtellina e Alto Lario-Cure Palliative, Sondrio; 3ASST della Valtellina e Alto
Lario-Anatomia Patologica, Sondrio; 4ASST della Valtellina e Alto LarioSenologia, Sondrio; 5ASST della Valtellina e Alto Lario-Breast Unit, Sondrio

Background: Breast cancer includes several biological
entities with different significance both from a prognostic
and clinical point of view. Her 2 low breast cancer represents a new entity whose prognostic characteristics and
predictive meaning are still unclear. However, the advent
of novel anti HER2 active agents in non amplified tumors
suggests the potential predictive role of Her 2 low.
Methods: A retrospective monocentric observational trial
has been proposed to define the characteristics of the HER
2 low population within our institution. Inclusion criteria
required patients with breast cancer who performed biopsy
and/or surgery from 1 January 2018 to 31 December 2019
with HER 2 with immunohistochemistry 1+ or 2+ with
negative ISH.

Tumori Journal Abstract Book - October 2020

Table of Contents for the Digital Edition of Tumori Journal Abstract Book - October 2020